Cyramza (ramucirumab) Patient Assistance Program
Don’t let the high cost of brand anti-VEGFR2 monoclonal antibody disrupt your gastric, NSCLC, colorectal, or hepatocellular cancer treatment. We help eligible patients access Cyramza (ramucirumab intravenous infusion) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
Key Takeaways:
- Cyramza (ramucirumab) is FDA-approved across multiple indications: gastric or gastroesophageal junction adenocarcinoma (monotherapy or with paclitaxel after platinum-based chemo), metastatic NSCLC (with docetaxel after platinum-based chemo, or with erlotinib first-line in EGFR-mutated NSCLC), metastatic colorectal cancer (with FOLFIRI after bevacizumab/oxaliplatin/fluoropyrimidine), and hepatocellular carcinoma after sorafenib with AFP ≥400 ng/mL. Anti-VEGFR2 fully human monoclonal antibody — antiangiogenic.
- Without assistance, Cyramza costs commonly run approximately $7,000–$11,000 per dose (every 2 or 3 weeks depending on regimen).
- Through AffordMyPrescriptions, qualifying patients can access Cyramza for a flat $69.95 per month.
- Other antiangiogenic therapies: bevacizumab (Avastin biosimilars now widely available — Mvasi, Zirabev — anti-VEGF-A ligand, broader indications), aflibercept (Zaltrap — anti-VEGF-A/B/PlGF, mCRC after FOLFOX), regorafenib (Stivarga — generic now, multi-kinase oral, mCRC), oral multi-kinase inhibitors targeting VEGFR (sunitinib generic, sorafenib generic, axitinib generic, pazopanib generic, lenvatinib/Lenvima, cabozantinib/Cabometyx). Indication-specific guideline-driven selection.
What is Cyramza Prescription Assistance Program?
The Cyramza Patient Assistance Program is a manufacturer-sponsored initiative that helps eligible patients access Cyramza (used across multiple cancer indications as an antiangiogenic anti-VEGFR2 monoclonal antibody) at little or no cost when they meet specific income, insurance, and clinical criteria. The program is free to apply for, but the enrollment process involves detailed applications, medical oncology coordination, indication-specific documentation, supporting documentation, and ongoing renewal — which can be overwhelming when you are managing advanced cancer.
At AffordMyPrescriptions, our Patient Advocates handle the entire Cyramza PAP enrollment for a flat $69.95 per month. We complete the application, coordinate with your oncologist for required medical documentation, follow up with the manufacturer’s program until approval, manage your infusion cycles, and handle annual re-certification — so you never face a gap in your Cyramza antiangiogenic therapy.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your Cyramza enrollment — from the initial application through ongoing refills and annual re-enrollment — so you never face a gap in your cancer treatment.
Pharmacy Price Comparison
- Without assistance, Cyramza costs thousands of dollars per infusion at oncology centers. Discount cards and pharmacy coupons offer minimal relief at this price point, but a Patient Assistance Program can make this targeted therapy accessible if you qualify. The table below compares typical pricing across major settings to what you'd pay with our Cyramza advocacy service:
| PHARMACY | PRICE (30-DAY) WITH BEST COUPONS | YOU SAVE W/ US |
|---|---|---|
| Regorafenib generic (alt) | ~$3,000/mo | Generic oral antiangiogenic |
| Hospital oncology | ~$10,500/dose | Save substantially |
| Community oncology | ~$9,000/dose | Save substantially |
| Specialty pharmacy | ~$8,000/dose | Save substantially |
| 340B-eligible institution | ~$7,000/dose | Save substantially |
| Avastin biosimilars (alt) | ~$2,500/dose | Cheaper VEGF alt |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. AffordMyPrescriptions Advocacy Service bypasses pharmacy pricing entirely by using the manufacturer’s assistance program to secure your Cyramza — independent of dosage or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Cyramza Prescription Program?
The Cyramza Patient Assistance Program is free to apply and provides medication at no cost if approved. But the process involves detailed applications, prescriber coordination, documentation, and ongoing management — applications that are commonly delayed or denied when paperwork is incomplete. Our $69.95 per month covers full advocacy: applications, doctor coordination, documentation, refill management, and re-enrollment — so you focus on your health, not paperwork. Bevacizumab biosimilars now substantially cheaper as alternative antiangiogenic option where appropriate.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for Cyramza assistance.
We Advocate
Our specialists gather documentation, complete applications, and coordinate with your prescriber and the assistance program.
Receive Medication
Once approved, your Cyramza is delivered through the assistance program while we manage refills and annual renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Cyramza:
Limitations of Coupons
Prices fluctuate — savings aren’t guaranteed month-to-month
Copay accumulators may prevent savings from counting toward your deductible
Coupon cards expire and require constant renewal
Still $7,000–$11,000/dose per month even with the best discount
Cannot be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
Medicare Part D patients accepted
If denied, we explore alternative savings paths on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Cyramza assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Cyramza Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Understanding Cyramza:
Cyramza is a fully human IgG1 anti-VEGFR2 monoclonal antibody that blocks VEGF binding to VEGFR2 — blocking downstream angiogenesis and tumor blood vessel formation. Differs from bevacizumab (anti-VEGF-A ligand) in directly blocking the receptor. Approved across gastric/GEJ, NSCLC, mCRC, and HCC indications based on multiple phase 3 trials (REGARD, RAINBOW, REVEL, RAISE, REACH-2).
How It Works:
Tumor angiogenesis is essential for tumor growth, invasion, and metastasis. VEGFR2 (vascular endothelial growth factor receptor 2) is the primary signaling receptor for VEGF-A on endothelial cells driving new blood vessel formation. Ramucirumab binds and blocks VEGFR2 — prevents VEGF binding and downstream proangiogenic signaling. Reduces tumor angiogenesis, normalizes existing tumor vasculature, and limits tumor growth and metastasis. Combination with chemotherapy or other targeted therapy extends survival in multiple cancers. Class antiangiogenic side effects include hypertension, proteinuria, bleeding, thromboembolism, and impaired wound healing.
Form and Use:
Cyramza IV infusion. Dosing varies by indication: 8 mg/kg every 2 weeks for gastric (REGARD/RAINBOW), CRC (RAISE — with FOLFIRI); 10 mg/kg every 3 weeks for NSCLC with docetaxel (REVEL); 8 mg/kg every 2 weeks for HCC (REACH-2); 10 mg/kg every 2 weeks for NSCLC EGFR-mutated with erlotinib (RELAY). Premedicate with H1 antihistamine. Monitor blood pressure (treat HTN), urinalysis (proteinuria), bleeding, wound healing concerns. Hold for surgery — 4 weeks before/after major surgery.
Generic Availability:
No biosimilar/generic. Other antiangiogenic therapies: bevacizumab (Avastin with biosimilars now widely available substantially cheaper — Mvasi/Zirabev — anti-VEGF-A ligand, broader indications including ovarian, glioblastoma, RCC, cervical, breast, mesothelioma, hepatocellular with atezolizumab), aflibercept (Zaltrap — anti-VEGF-A/B/PlGF, mCRC after FOLFOX), regorafenib (Stivarga — generic now available, multi-kinase oral, mCRC, GIST, HCC), oral multi-kinase VEGFR-targeting inhibitors (sunitinib/Sutent generic for RCC/GIST/pNET, sorafenib/Nexavar generic for RCC/HCC/thyroid, axitinib/Inlyta generic for RCC, pazopanib/Votrient generic for RCC/STS, lenvatinib/Lenvima for thyroid/HCC/RCC/EC, cabozantinib/Cabometyx for RCC/HCC/thyroid). Standard chemotherapy backbones (generic) per cancer type and indication. Checkpoint inhibitor combinations (Keytruda, Opdivo, Tecentriq, Imfinzi) per FDA-approved indications. NCCN guidelines per cancer type guide selection.
Warnings:
Boxed warnings: hemorrhage (severe, sometimes fatal — including gastrointestinal hemorrhage; do not give to patients with severe hemorrhage), GI perforation (rare but potentially fatal — evaluate severe abdominal pain), impaired wound healing (hold for surgery — 4 weeks before and after major procedures). Other antiangiogenic class effects: arterial thromboembolic events (MI, stroke — increased risk), venous thromboembolic events, hypertension (very common — monitor BP, treat aggressively; permanent discontinuation for severe uncontrolled HTN), proteinuria (monitor urine; hold for high-grade proteinuria or nephrotic syndrome), infusion-related reactions, reversible posterior leukoencephalopathy syndrome (PRES), clinical deterioration in Child-Pugh B/C cirrhosis, fistula formation, congestive heart failure (with docetaxel), embryo-fetal toxicity. Indication-specific contraindications and warnings (e.g., variceal bleeding risk in HCC).
FAQ (Frequently Asked Questions)
How much does Cyramza cost without insurance?
$7,000–$11,000 per dose. Annualized cost can exceed $200,000 depending on regimen. Bevacizumab biosimilars (Mvasi, Zirabev) are substantially cheaper alternative antiangiogenic options where appropriate.
What is the difference between Cyramza and Avastin (bevacizumab)?
Both block VEGF signaling but at different points. Avastin (bevacizumab) is an anti-VEGF-A ligand — blocks the VEGF molecule. Cyramza (ramucirumab) is anti-VEGFR2 — blocks the receptor. Bevacizumab has broader FDA-approved indications. With biosimilars now widely available, bevacizumab is substantially cheaper than Cyramza.
Is Cyramza considered chemotherapy?
No — Cyramza is a targeted antiangiogenic monoclonal antibody. Different mechanism from chemotherapy, though typically combined with chemotherapy in most regimens.
What are the FDA boxed warnings for Cyramza?
Severe hemorrhage (sometimes fatal — including GI bleeding), GI perforation (rare but potentially fatal), and impaired wound healing (must hold 4 weeks before and after major surgery).
Why is blood pressure monitoring important on Cyramza?
Hypertension is very common with antiangiogenic class — monitor BP at baseline and frequently during therapy. Aggressive antihypertensive management is appropriate. Permanent discontinuation for severe uncontrolled HTN. Treatment of hypertension is generally with standard antihypertensives.
Take Control of Your Medication Costs
Antiangiogenic targeted therapy for advanced cancer should not be derailed by cost. Bevacizumab biosimilars are substantially cheaper alternatives for appropriate indications. Our Cyramza advocacy team is ready to verify your eligibility, complete the manufacturer application on your behalf, and manage your prescription through approval, delivery, and renewal — for a flat $69.95 per month. If we cannot help you access Cyramza through a Patient Assistance Program, you are not charged.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.